Search Result

Results for "

ventricular tachycardia

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adrenergic Receptor (5) ATP Synthase (1) Calcium Channel (7) Drug Derivative (1) Drug Metabolite (1) Isotope-Labeled Compounds (2) Myosin (1) Opioid Receptor (1) Parasite (1) Potassium Channel (7) Reference Standards (2) Sodium Channel (5)
By Research Areas:	Cancer (2) Cardiovascular Disease (19) Infection (1) Inflammation/Immunology (1) Neurological Disease (2)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-W010950

Flecainide 3 Publications Verification	Potassium Channel Sodium Channel	Cardiovascular Disease
Flecainide is an orally active antiarrhythmic agent. Flecainide can block sodium channels and inhibit calcium ion release mediated by the cardiac ryanodine receptor (RyR2). Flecainide can be used in the research of diseases such as catecholaminergic polymorphic ventricular tachycardia (CPVT) .

HY-119850

Aladorian ARM036; S44121	Calcium Channel	Cardiovascular Disease
Aladorian (ARM036; S44121) is a non-peptidic ryanodine receptor 2 (RyR2) stabilizer. Aladorian stabilizes RyR2 channels and rectifies abnormal Ca²⁺ handling in cardiomyocytes. Aladorian improves cardiomyocyte Ca²⁺ homeostasis independent of dystrophin restoration. Aladorian attenuates early cardiomyopathy and enhances left ventricular function in a canine muscular dystrophy model. Aladorian can be used for the research of heart failure, Duchenne muscular dystrophy-associated cardiomyopathy and muscular dystrophy .

HY-149662

TMDJ-035	Calcium Channel ATP Synthase Myosin	Cardiovascular Disease
TMDJ-035 is a high-affinity, selective RyR2 inhibitor with an EC₅₀ of 0.0130 μM. TMDJ-035 reduces RyR2 protein expression without affecting action potential-induced Ca ²⁺ transients. TMDJ-035 decreases ATP content and intracellular Ca ²⁺ levels. TMDJ-035 inhibits arrhythmias in a CPVT mouse model carrying mutant RyR2s. TMDJ-035 has no effect on electrocardiogram parameters or cardiac systolic function. TMDJ-035 exacerbates heart failure in mouse myocardial infarction models and hypoxic cardiomyocytes by altering cardiac function, causing tissue damage, promoting inflammatory infiltration, collagen deposition, and changes in Myosin heavy chain/actin expression. TMDJ-035 can be used in studies related to heart failure, catecholaminergic polymorphic ventricular tachycardia, and arrhythmias .

HY-14304A

Zinterol hydrochloride 1 Publications Verification MJ 9184 hydrochloride	Adrenergic Receptor	Cardiovascular Disease
Zinterol hydrochloride (MJ 9184 hydrochloride) is a potent and selective β2-adrenoceptor agonist . Zinterol hydrochloride increases I_Ca in a concentration-dependent manner with an EC₅₀ of 2.2 nM . Zinterol hydrochloride induces ventricular arrhythmias in conscious heart failure rabbits .

HY-W010950A

Flecainide hydrochloride 3 Publications Verification	Potassium Channel Sodium Channel	Cardiovascular Disease
Flecainide hydrochloride is an orally active antiarrhythmic agent. Flecainide hydrochloride can block sodium channels and inhibit calcium ion release mediated by the cardiac ryanodine receptor (RyR2). Flecainide hydrochloride can be used in the research of diseases such as catecholaminergic polymorphic ventricular tachycardia (CPVT) .

HY-B0006C

(R)-Carvedilol (R)-BM 14190	Adrenergic Receptor Calcium Channel	Cardiovascular Disease Cancer
(R)-Carvedilol ((R)-BM 14190) is the orally active R-isomer of Carvedilol (HY-B0006). (R)-Carvedilol has α-receptor blocking activity but no β-receptor blocking activity. (R)-Carvedilol inhibits spontaneous Ca ²⁺ waves. (R)-Carvedilol inhibits stress-induced ventricular tachycardia and delays the development of UV-induced skin tumors and reduces their malignancy .

HY-N1924

Crassicauline A Crassicaulin A	Parasite	Cardiovascular Disease Infection
Crassicauline A (Crassicaulin A) is a diester-type diterpenoid alkaloid. Crassicauline A exhibits feeding deterrent activity against adult Tribolium castaneum, with a EC₅₀ of 1134.5 ppm. Crassicauline A induces arrhythmia at a dose of 0.10 mg/kg .

HY-16094

Bethanidine sulfate BW 467C60	Adrenergic Receptor	Cardiovascular Disease Neurological Disease
Bethanidine sulfate (BW 467C60) is an orally active antihypertensive agent and adrenergic neuron blocker. Bethanidine sulfate exerts its antihypertensive effect by inhibiting the release of norepinephrine from sympathetic nerve terminals. Bethanidine sulfate exhibits anti-ventricular arrhythmic activity. Bethanidine sulfate can be used in research related to hypertension, ventricular tachycardia, and ventricular fibrillation .

HY-W010950S

Flecainide-d3	Potassium Channel Sodium Channel Isotope-Labeled Compounds	Cardiovascular Disease
Flecainide-d₃ is the deuterium labeled Flecainide. Flecainide is an orally active antiarrhythmic agent. Flecainide can block sodium channels and inhibit calcium ion release mediated by the cardiac ryanodine receptor (RyR2). Flecainide can be used in the research of diseases such as catecholaminergic polymorphic ventricular tachycardia (CPVT) .

HY-10486

JDTic	Opioid Receptor	Neurological Disease
JDTic is a blood-brain barrier-permeable κ-opioid receptor antagonist (K_i=0.02 nM) with favorable in vitro ADME properties. JDTic blocks agonist-mediated Gi and β-arrestin signaling pathways as well as analgesic effects by stabilizing the inactive conformation of hKOR and activating JNK. JDTic may also induce transient asymptomatic ventricular tachycardia. JDTic is widely applicable to studies related to depression, anxiety, stress-induced addictive behaviors, and nicotine withdrawal .

HY-113322

3-Hydroxyquinine 3-Hydroxyquinidine	Drug Metabolite	Cardiovascular Disease
3-Hydroxyquinine is a metabolite of Quinidine (HY-B1751). 3-Hydroxyquinine prevents ventricular fibrillation and ventricular tachycardia after coronary reperfusion in an isolated rat heart reperfusion arrhythmia model in a concentration-dependent manner. 3-Hydroxyquinine can be used in the study of cardiac arrhythmias .

HY-14304

Zinterol MJ 9184	Adrenergic Receptor	Cardiovascular Disease
Zinterol (MJ 9184) is a potent and selective β2-adrenoceptor agonist . Zinterol increases I_Ca in a concentration-dependent manner with an EC₅₀ of 2.2 nM .

HY-116500A

AH-1058	Calcium Channel	Cardiovascular Disease
AH-1058 is a newly synthesized antiarrhythmic agent that exhibits significant antiarrhythmic activity by delaying premature ventricular complexes and ventricular fibrillation in experimental arrhythmia models. AH-1058 effectively inhibits both ventricular tachycardia and ventricular fibrillation in the reperfusion-induced arrhythmia model in rats. AH-1058 demonstrates potent calcium channel-blocking effects, suppressing L-type Ca2+ currents in isolated cardiomyocytes.

HY-116759

VU0405601	Potassium Channel	Cardiovascular Disease
VU0405601 is a potent KV11.1 channel activator. VU0405601 protects cardiac tissue from dofetilide (HY-B0232)-induced ventricular tachycardia .

HY-119850A

Aladorian sodium ARM036 sodium; S44121 sodium	Calcium Channel	Cardiovascular Disease
Aladorian (ARM036; S44121) sodium is a non-peptidic ryanodine receptor 2 (RyR2) stabilizer. Aladorian sodium stabilizes RyR2 channels and rectifies abnormal Ca²⁺ handling in cardiomyocytes. Aladorian sodium improves cardiomyocyte Ca ²⁺ homeostasis independent of dystrophin restoration. Aladorian sodium attenuates early cardiomyopathy and enhances left ventricular function in a canine muscular dystrophy model. Aladorian sodium can be used for the research of heart failure, Duchenne muscular dystrophy-associated cardiomyopathy and muscular dystrophy .

HY-W010950AR

Flecainide hydrochloride (Standard)	Reference Standards Potassium Channel Sodium Channel	Cardiovascular Disease
Flecainide hydrochloride is an orally active antiarrhythmic agent. Flecainide hydrochloride can block sodium channels and inhibit calcium ion release mediated by the cardiac ryanodine receptor (RyR2). Flecainide hydrochloride can be used in the research of diseases such as catecholaminergic polymorphic ventricular tachycardia (CPVT) .

HY-W010950R

Flecainide (Standard)	Reference Standards Potassium Channel Sodium Channel	Cardiovascular Disease
Flecainide (Standard) is the analytical standard of Flecainide. This product is intended for research and analytical applications. Flecainide is an orally active antiarrhythmic agent. Flecainide can block sodium channels and inhibit calcium ion release mediated by the cardiac ryanodine receptor (RyR2). Flecainide can be used in the research of diseases such as catecholaminergic polymorphic ventricular tachycardia (CPVT) .

HY-B0006CS

(R)-Carvedilol-d4 (R)-BM 14190-d₄	Isotope-Labeled Compounds Adrenergic Receptor Calcium Channel	Cardiovascular Disease Cancer
(R)-Carvedilol-d₄ is deuterium labeled (R)-Carvedilol (HY-B0006C). (R)-Carvedilol ((R)-BM 14190) is the orally active R-isomer of Carvedilol (HY-B0006). (R)-Carvedilol has α-receptor blocking activity but no β-receptor blocking activity. (R)-Carvedilol inhibits spontaneous Ca ²⁺ waves. (R)-Carvedilol inhibits stress-induced ventricular tachycardia and delays the development of UV-induced skin tumors and reduces their malignancy .

HY-105439A

Clofilium phosphate LY 150378	Drug Derivative	Cardiovascular Disease
Clofilium phosphate (LY 150378) is an antiarrhythmic/antifibrillatory agent. Clofilium phosphate significantly prolongs the action potential duration and effective refractory period of canine cardiac Purkinje fibers, increases the ventricular fibrillation threshold, reduces the risk of reentrant arrhythmias, and enables spontaneous conversion of some ventricular fibrillation episodes to sinus rhythm. Clofilium phosphate is applicable to research related to ventricular fibrillation, arrhythmias, and ventricular tachyarrhythmias .

HY-183206

UR 8225	Potassium Channel Calcium Channel	Cardiovascular Disease Inflammation/Immunology
UR 8225 is an orally active ATP-sensitive K ⁺ channel activator with vasodilator, smooth muscle relaxant, antihypertensive, and bronchodilator activities. UR 8225 induces membrane hyperpolarization by increasing outward K ⁺ conductance and reduces Ca ²⁺ influx through voltage-gated L-type Ca ²⁺ channels. UR 8225 reduces total peripheral vascular resistance, shortens cardiac action potential duration, inhibits agonist-induced Ca ²⁺ influx, and stimulates renin release. UR 8225 induces reflex tachycardia but lacks β-adrenergic receptor blocking activity. UR 8225 is widely applicable to research in fields related to hypertension, myocardial ischemia, ventricular fibrillation, and other conditions .

Cat. No.	Product Name	Target	Research Area

HY-P5494

DPc10	Peptides	Others
DPc10 is a biological active peptide. (This is amino acids 2460 to 2495 fragment of cardiac ryanodine receptor (RyR2). RyR2 controls calcium release from the sarcoplasmic reticulum, which begins muscle contraction. Mutated RyR2 is associated to ventricular tachycardia (VT) and sudden death.)

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N1924

Crassicauline A Crassicaulin A	Alkaloids Structural Classification Other Alkaloids Ranunculaceae Aconitum carmichaeli Debx. Plants Source Classification	Parasite
Crassicauline A (Crassicaulin A) is a diester-type diterpenoid alkaloid. Crassicauline A exhibits feeding deterrent activity against adult Tribolium castaneum, with a EC₅₀ of 1134.5 ppm. Crassicauline A induces arrhythmia at a dose of 0.10 mg/kg .

Cat. No.	Product Name	Chemical Structure

HY-W010950S

Flecainide-d3
Flecainide-d₃ is the deuterium labeled Flecainide. Flecainide is an orally active antiarrhythmic agent. Flecainide can block sodium channels and inhibit calcium ion release mediated by the cardiac ryanodine receptor (RyR2). Flecainide can be used in the research of diseases such as catecholaminergic polymorphic ventricular tachycardia (CPVT) .

HY-B0006CS

(R)-Carvedilol-d4
(R)-Carvedilol-d₄ is deuterium labeled (R)-Carvedilol (HY-B0006C). (R)-Carvedilol ((R)-BM 14190) is the orally active R-isomer of Carvedilol (HY-B0006). (R)-Carvedilol has α-receptor blocking activity but no β-receptor blocking activity. (R)-Carvedilol inhibits spontaneous Ca ²⁺ waves. (R)-Carvedilol inhibits stress-induced ventricular tachycardia and delays the development of UV-induced skin tumors and reduces their malignancy .

(R)-Carvedilol-d4

(R)-Carvedilol-d₄ is deuterium labeled (R)-Carvedilol (HY-B0006C). (R)-Carvedilol ((R)-BM 14190) is the orally active R-isomer of Carvedilol (HY-B0006). (R)-Carvedilol has α-receptor blocking activity but no β-receptor blocking activity. (R)-Carvedilol inhibits spontaneous Ca ²⁺ waves. (R)-Carvedilol inhibits stress-induced ventricular tachycardia and delays the development of UV-induced skin tumors and reduces their malignancy .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks